Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.'
Automated insulin technology developer Insulet posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier.
Source: marketwatch.com
Stay updated with breaking news from Glenn Shell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Automated insulin technology developer Insulet posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier.
The company, which participated in an Ohio State accelerator, uses AI to generate tech and science insights from public sites and open-source data.